Please login to the form below

Not currently logged in
Email:
Password:

Novartis US appeals halt generic Famvir

Novartis says that a US court halted Israeli-based Teva's sale of a generic version of its Famvir genital herpes treatment

Novartis has said that that a US court has halted Israeli-based Teva's sale of a generic version of its Famvir (famciclovir) genital herpes treatment.

The Swiss-headquartered company said the injunction by the US Court of Appeals for the Federal Circuit was issued on 8 September, two days after a district court in New Jersey denied Novartis' motion to stop Israel's Teva from marketing its version of the drug.

The injunction requires Teva to submit a response by 11 September 2007, Novartis revealed in a company statement.

Novartis shares were down 0.4 per cent at CHF 63.25 (USD 53.27) on the Zurich stock exchange on 10 September 2007.

10th September 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Planning your clinical trial? Why you need to engage patients sooner
It’s highly likely that clinical studies are deterring patients based on decisions made in the early stages, such as during planning and design....
Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...

Infographics